Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 14/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8172506 | 0.94 | HDAC4 (0.69) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL22560048 | 0.88 | L3MBTL1 (0.63) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6296181 | 0.88 | HDAC4 (0.75) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL517309 | 0.88 | HDAC4 (0.81) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL7842320 | 0.86 | HDAC4 (0.68) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6665592 | 0.86 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6669511 | 0.86 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL1065393 | 0.86 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL137348 | 0.86 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL7837978 | 0.85 | HDAC4 (0.71) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208606-B2 | Hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol | SHELL OIL COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208606-B2 | Hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol | SHELL OIL COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| US-7186868-B2 | Hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol | SHELL OIL COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186868-B2 | Hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol | SHELL OIL COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070032687-A1 | Hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol | SHELL USA, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032687-A1 | Hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol | SHELL USA, INC. | 2007-02-08 | — | — | US | disclosed |
| US-5691349-A | ANTICHOLESTEROL AGENTS; ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 1997-11-25 | — | — | US | disclosed |
| EP-0654032-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LTD (GB) | 1997-10-15 | — | — | EP | disclosed |
| EP-0654032-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS. | ZENECA LTD (GB) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003451-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032687-A1 | Hydroformylation process for the conversion of an ethylenically unsaturated compound to an alcohol | ADH1C, ADH1A, ADH5 | HDAC4 3823/4885HDAC1 4763/4885HDAC7 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.